MONTREAL – April 8, 2026 – The annual Society for Cardiovascular Angiography & Interventions (SCAI) meeting, SCAI Scientific Sessions 2026 & CAIC-ACCI Summit, will commence on Thursday, April 23, 2026, bringing thousands of researchers, clinicians, scientists, and innovators from around the world together to explore recent breakthroughs in the fields of interventional cardiology and endovascular medicine. Partnering with the Canadian Association of Interventional Cardiology/Association Canadienne de cardiologie d’intervention (CAIC-ACCI), the joint international conference will be held at the Palais des Congrès de Montréal in Montréal, Canada, from Thursday, April 23 to Saturday, April 25.

Insilico Medicine (03696.HK), a clinical-stage, generative AI-driven drug discovery company, today announced the nomination of ISM6200 as a potent, potentially best-in-class preclinical candidate (PCC) targeting NR3C1, for the treatment of ovarian cancer, Hypercortisolism (Cushing’s Syndrome), and other disorders related to excess cortisol including obesity. The process was empowered by Chemistry42, the generative chemistry engine affiliated to Insilico’s Pharma.AI, as well as the specialized applications across the molecule discovery and optimization cycle. 

Psychological stress during pregnancy is known to affect birth outcomes, but isolating its effects has been difficult. Researchers found that babies born in Japan immediately after the Fukushima nuclear accident were more likely to be born preterm or with low birth weights. Radiation exposure-related maternal anxieties significantly contributed to the differences in birth outcomes. The findings underscore the importance of clear communication and psychological support for pregnant women during crises to help prevent intergenerational harm.

Septic shock is a major cause of mortality, especially among patients who need continuous renal replacement therapy (CRRT). A new study compared two widely used extracorporeal blood purification strategies (CytoSorb^Ⓡand oXiris^Ⓡ). Both strategies showed comparable clinical outcomes. Both approaches were associated with improved hemodynamic parameters, including reduced vasopressor requirements and lactate levels. No significant differences were found in vasopressor-free days, ICU stay, or mortality, highlighting the need for larger prospective trials.

Antibody therapies have been used to treat diseases for nearly two decades, but their association with harmful immune reactions, including anaphylaxis, remains unclear. Researchers from Chiba University examined how antibodies interact with Fcγ receptors in tumor-bearing mouse models and found that strong Fcγ receptor binding was associated with higher antidrug antibody levels and anaphylaxis, with tumor-associated myeloid cells implicated in this process. These findings may help guide the development of safer antibody therapies.

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer. The primary analysis of Alliance A221805 was published in JCO Oncology Advances.

A new University at Buffalo study finds that Americans produce similar amounts of plastic packaging waste no matter their income, education, or location. However, wealthier and more educated communities recycle significantly more. The study suggests this gap is largely due to unequal access to recycling infrastructure, making it harder for some communities to recycle effectively.